PSAidis an at home PSA level monitoring device currently in the final stages of development. Our product enables customers to keep track of their PSA levels from the comfort of their own home and view their results on an accompanying app. This avoids the high costs associated with the time-consuming process of having PSA levels monitored in hospitals. In the box, patients will find everything they need to obtain a quantitative PSA result whilst having any influential factors considered. Once the sample is inserted into the device, the colour light sensor will measure the level of PSA in the sample and provide this result within 10 minutes. The result will be sent to the patients’ phone via Wi-Fi and can be viewed on the PSAid application. The test results obtained will be shared with the patient’s doctor via our secure server and the doctor will advise the patient on any follow up steps to be taken via the app. The colour light sensor that provides the test result will be purchased online and connected to a PCB where the data will be interpreted and sent to the app. Remedy Ltd. aims to resolve the difficulties faced by prostate cancer patients in monitoring their PSA levels post diagnosis. PSA (Prostate Specific Antigen) levels are a key indicator in
determining the stage a patient’s prostate cancer is at, therefore, keeping a close eye on a patient’s PSA levels post diagnosis is vital in preventing development of the illness into terminal metastatic prostate cancer. Currently, patients must travel to their doctor frequently to have their PSA levels monitored. This causes issues for many prostate cancer patients who suffer from side effects such as incontinence and they find it difficult to sit for long periods of time. PSA level monitoring from home is an option but it is inefficient due to long wait times for results, high cost and inaccuracy. This is costly for both the patient and the already overburdened healthcare system. Current home PSA testing lacks quantitative results, takes days for results to process and is an unsustainable means of PSA monitoring due to the throwaway nature of current devices. Remedy have received first place in the Bolton Trust student enterprise competition with the PSAid. This then led the company to competing in the German-based, Stage Two competition, Europes first international university enterprise competition.